Therapy With Verapamil or Carvedilol in Chronic Heart Failure
Information source: Medical University of Silesia
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Dilated Cardiomyopathy
Intervention: Verapamil (Drug); Carvedilol (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Medical University of Silesia Official(s) and/or principal investigator(s): Jan Wodniecki, Prof., Study Chair, Affiliation: Medical University of Silesia
Overall contact: Jan Wodniecki, MD, PhD, Phone: +48 32 2716471, Ext: 228, Email: wojnicz@dom.zabrze.pl
Summary
The aim of this study is to compare the effect of treatment with verapamil or carvedilol on
long-term outcomes in stable, chronic heart failure secondary to non-ischemic
cardiomyopathy.
Clinical Details
Official title: Prospective, Randomized Comparison of Therapy With Verapamil or Carvedilol on Long-Term Outcomes of Patients With Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment
Primary outcome: Sserum level of NT-proBNP,LVEF, LV diameters, exercise capacity (NYHA, V02,6 min walking test, changes in quality of life (MLHFQ).In addition to secondary endpoints efficacy, patients will be classified as improved if they meet an increase of > 10 percentage points in the absolute EF and decrease in NT-proBNP levels at least 50% as compared with baseline study.
Secondary outcome: Combined: mortality, heart transplantation, and readmission to hospital due to heart failure progression
Detailed description:
Heart failure, irrespective of its etiology may be viewed as a progressive disorder
initiated by a different events and sustained by a multifaceted pathophysiological
mechanisms. Regardless of the nature of the initiating events and optimized therapy used,
loss of functioning cardiac myocytes developed and the disease progressed. One potential
explanation for such progression is that not all pathological mechanisms underlying the
disease are antagonized enough by currently used therapeutic strategy. Accordingly, impaired
myocardial perfusion secondary to microvascular dysfunction has been postulated to play a
major role in the progression of heart failure despite standard therapy for heart failure.
It has been hypothesized that diffuse subendocardial ischemia due to altered coronary
physiology may contribute to the global cardiac dysfunction seen in heart failure patients.
Accordingly, coronary endothelial dysfunction at the microvascular and epicardial level in
patients with acute-onset idiopathic dilated cardiomyopathy and chronic congestive heart
failure has been reported. Thus, taking all mentioned above into account, the improvement in
endothelial function and diminishing of subendocardial ischemia with calcium antagonists may
be promising in terms of using these drugs for therapy of patients with stable chronic heart
failure. The previous randomized study (5) and our long-term pilot study support this point
of view.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chronic heart failure (NYHA II and III; LV ejection fraction, ≤ 35%) secondary to
non-ischemic cardiomyopathy
- Stable condition at least 6 months before enrollment on conventional therapy
(beta-blockers, ACE inhibitors and diuretics).
Exclusion Criteria:
- Improvement in clinical status on conventional therapy in out-patients period
preceded hospitalization,
- Any changes narrowing epicardial coronary arteries in coronary angiography,
- Insulin dependent diabetes,
- Valvular heart disease (except the relative mitral regurgitation),
- Endocrine disease
- Significant renal and liver disease
- Alcohol abuse
- Lack of written informed consent
Locations and Contacts
Jan Wodniecki, MD, PhD, Phone: +48 32 2716471, Ext: 228, Email: wojnicz@dom.zabrze.pl
Silesian Centre for Heart Disease, 3rd Department of Cardiology, Zabrze, Szpitalna 2 st. 41800, Poland; Recruiting Romuald Wojnicz, MD, PhD, Principal Investigator Ewa N Kozielska, MD, PhD, Sub-Investigator Jolanta Nowak, MD, Sub-Investigator Krzysztof Wilczek, MD, Sub-Investigator Celina Wojciechowska, MD, Sub-Investigator Bozena Szygula, MD, Sub-Investigator
Additional Information
Starting date: January 2006
Last updated: September 8, 2006
|